Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Mt. Sinai researchers report that aspirin reduces risk of first heart attack by one-third


Aspirin reduces the risk of a first heart attack by 32 percent, according to a report by researchers at Mount Sinai Medical Center & Miami Heart Institute (MSMC-MHI) published in the current issue of Archives of Internal Medicine. The paper, which is based on a meta-analysis of five major randomized clinical trials (55,580 participants, 11,466 women) in primary prevention, also found that aspirin reduces the combined risk of heart attack, stroke and vascular death by 15 percent.

Charles H. Hennekens, M.D., Co-Director of Cardiovascular Research at MSMC-MHI, and Professor of Medicine & Epidemiology and Public Health at the University of Miami School of Medicine was the first to demonstrate the benefit of aspirin in reducing the risk of a first heart attack in a landmark Physicians’ Health Study (PHS), which was published in 1988 in the New England Journal of Medicine. Under his direction, Rachel S. Eidelman, M.D., a cardiology fellow at MSMC-MHI, performed the latest meta-analysis.

The findings strongly support the treatment guidelines issued by the American Heart Association (AHA), which recommends the use of aspirin for all men and women whose 10-year risks of a first coronary event are 10 percent or greater. The U.S. Preventive Services Task Force (USPSTF) released similar guidelines earlier in 2002, urging all healthcare providers to consider the use of aspirin in all apparently healthy men and women with a 6 percent or greater 10-year risk of a coronary event.

"The individual trials and their meta-analysis support the AHA and USPSTF guidelines, which note that the benefits of long-term aspirin use are likely to outweigh any risks for these individuals," Hennekens said. "The more widespread and appropriate use of aspirin in primary prevention could avoid hundreds of thousands of first heart attacks and important vascular events each year in the U.S."

The aspirin component of Dr. Hennekens trial, the PHS, was terminated early on January 25, 1988 based on the unanimous recommendations of the Data and Safety Monitoring Board, due primarily to a statistically extreme 44 percent reduction in risk of a first heart attack among those assigned at random to aspirin. There have been four primary prevention trials published since then, three of which showed similar positive findings for aspirin.

"We found that the current totality of evidence strongly supports our initial findings from the Physicians’ Health Study that aspirin significantly reduces the risk of a first heart attack in apparently healthy individuals," Hennekens added. "This data, along with the findings that aspirin reduces the risk of death by 23 percent if given during a heart attack and by 15 percent in a wide range of people who have survived prior cardiovascular events, demonstrate the need for wider utilization of aspirin."

"Yet despite the clearly demonstrated cardio-protective benefits of aspirin, this medication remains alarmingly underutilized among survivors of prior events, those having a heart attack and apparently healthy men and women, whose 10-year risk is 10 percent or more," Hennekens continued. "We hope the latest findings result in greater awareness on the part of healthcare providers and the general public and motivate increased aspirin utilization, which could result in significant reductions of premature cardiovascular deaths and first heart attacks."

Coronary heart disease is the single leading cause of death in the United States, accounting for more than 500,000 deaths annually. Approximately 80 percent of deaths from coronary heart disease in people under age 65 occur during the first heart attack.

Mount Sinai & Miami Heart’s Cardiovascular Center of Excellence is committed to being a leader in the prevention, diagnosis and treatment of heart disease. The medical center is the largest cardiac services provider in South Florida, conducting approximately 1,300 open heart procedures and approximately 7,400 diagnostic and therapeutic cardiac catheterizations annually.

For a physician referral, please call (305) 674-2273

Katie Cline | EurekAlert!

More articles from Health and Medicine:

nachricht NIH scientists describe potential antibody treatment for multidrug-resistant K. pneumoniae
14.03.2018 | NIH/National Institute of Allergy and Infectious Diseases

nachricht Researchers identify key step in viral replication
13.03.2018 | University of Pittsburgh Schools of the Health Sciences

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Locomotion control with photopigments

Researchers from Göttingen University discover additional function of opsins

Animal photoreceptors capture light with photopigments. Researchers from the University of Göttingen have now discovered that these photopigments fulfill an...

Im Focus: Surveying the Arctic: Tracking down carbon particles

Researchers embark on aerial campaign over Northeast Greenland

On 15 March, the AWI research aeroplane Polar 5 will depart for Greenland. Concentrating on the furthest northeast region of the island, an international team...

Im Focus: Unique Insights into the Antarctic Ice Shelf System

Data collected on ocean-ice interactions in the little-researched regions of the far south

The world’s second-largest ice shelf was the destination for a Polarstern expedition that ended in Punta Arenas, Chile on 14th March 2018. Oceanographers from...

Im Focus: ILA 2018: Laser alternative to hexavalent chromium coating

At the 2018 ILA Berlin Air Show from April 25–29, the Fraunhofer Institute for Laser Technology ILT is showcasing extreme high-speed Laser Material Deposition (EHLA): A video documents how for metal components that are highly loaded, EHLA has already proved itself as an alternative to hard chrome plating, which is now allowed only under special conditions.

When the EU restricted the use of hexavalent chromium compounds to special applications requiring authorization, the move prompted a rethink in the surface...

Im Focus: Radar for navigation support from autonomous flying drones

At the ILA Berlin, hall 4, booth 202, Fraunhofer FHR will present two radar sensors for navigation support of drones. The sensors are valuable components in the implementation of autonomous flying drones: they function as obstacle detectors to prevent collisions. Radar sensors also operate reliably in restricted visibility, e.g. in foggy or dusty conditions. Due to their ability to measure distances with high precision, the radar sensors can also be used as altimeters when other sources of information such as barometers or GPS are not available or cannot operate optimally.

Drones play an increasingly important role in the area of logistics and services. Well-known logistic companies place great hope in these compact, aerial...

All Focus news of the innovation-report >>>



Industry & Economy
Event News

Ultrafast Wireless and Chip Design at the DATE Conference in Dresden

16.03.2018 | Event News

International Tinnitus Conference of the Tinnitus Research Initiative in Regensburg

13.03.2018 | Event News

International Virtual Reality Conference “IEEE VR 2018” comes to Reutlingen, Germany

08.03.2018 | Event News

Latest News

Wandering greenhouse gas

16.03.2018 | Earth Sciences

'Frequency combs' ID chemicals within the mid-infrared spectral region

16.03.2018 | Physics and Astronomy

Biologists unravel another mystery of what makes DNA go 'loopy'

16.03.2018 | Life Sciences

Science & Research
Overview of more VideoLinks >>>